PREVENTING BRAIN METASTASES WITH ALECTINIB IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER: ECONOMIC IMPACT UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Kashiura, D. [1 ]
Santos, M. [2 ]
Carmo, L. [1 ]
Leme-Souza, R. [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Sao Paulo, SP, Brazil
[2] Brasilia Univ, UNESCO Chair Bioeth, Brasilia, DF, Brazil
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.253
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN129
引用
收藏
页码：S80 / S80
页数：1
相关论文
共 50 条
  • [1] Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer
    Burudpakdee, C.
    Wong, W.
    Seetasith, A.
    Corvino, F. A.
    Yeh, W.
    Gubens, M.
    LUNG CANCER, 2018, 119 : 103 - 111
  • [2] Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases
    Lockney, Natalie A.
    Wu, Abraham J.
    JOURNAL OF THORACIC DISEASE, 2017, 9 (02) : E152 - E154
  • [3] Treatment of brain metastases in ALK-positive non-small cell lung cancer
    Ceddia, Serena
    Codacci-Pisanelli, Giovanni
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 165
  • [4] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [5] Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer
    Nishi, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
  • [6] Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Ozasa, Hiroaki
    Sakamori, Yuichi
    Tsuji, Takahiro
    Nomizo, Takashi
    Yasuda, Yuto
    Yamamoto, Tomoko
    Ajimizu, Hitomi
    Hirai, Toyohiro
    IN VIVO, 2018, 32 (06): : 1587 - 1590
  • [7] BUDGET IMPACT ANALYSIS OF CRIZOTINIB IN THE TREATMENT OF ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
    Alexandre, R. F.
    Squiassi, H. B.
    Santana, C. F.
    VALUE IN HEALTH, 2017, 20 (05) : A97 - A98
  • [8] THE ECONOMIC IMPACT OF DELAYING BRAIN METASTASES IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE COMMERCIALLY INSURED US POPULATION
    Wong, W.
    Burudpakdee, C.
    Seetasith, A.
    Corvino, P.
    Yeh, D.
    Gubens, M.
    VALUE IN HEALTH, 2017, 20 (05) : A105 - A105
  • [9] ALECTINIB FOR THE TREATMENT OF ALK-POSITIVE STAGE IV NON-SMALL CELL LUNG CANCER
    Wong, K. M.
    Noonan, S.
    O'Bryant, C.
    Jimeno, A.
    DRUGS OF TODAY, 2015, 51 (03) : 161 - 170
  • [10] Alectinib for ALK-positive non-small-cell lung cancer
    Rossi, Antonio
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (08) : 1005 - 1013
12345